Sangamo Therapeutics has initiated a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration for its investigational gene therapy, isaralgagene civaparvovec (ST-920). This procedural step, commenced yesterday, represents a significant transition for the Fabry disease treatment candidate, moving it from clinical development into the formal regulatory review phase.
Accelerated Approval Pathway in Focus
The submission leverages data from the clinical STAAR study. A central focus of the trial was monitoring patient kidney function. Results at the 52-week mark demonstrated a positive mean annualized change in the estimated glomerular filtration rate (eGFR).
Crucially, the FDA has formally recognized this eGFR metric as the primary endpoint. This acceptance satisfies a fundamental requirement for the therapy to be reviewed under the Accelerated Approval program. This regulatory pathway is designed to expedite market access for drugs targeting serious rare diseases when they show promise of providing a clear therapeutic benefit.
Should investors sell immediately? Or is it worth buying Sangamo Therapeutics?
Companion Diagnostic Also Under Review
In a related development, the regulatory agency has accepted for review a companion diagnostic assay submitted alongside the therapy. This diagnostic test is intended to identify patients who are suitable candidates for the treatment prior to administration.
The long-term potential of the gene therapy to stabilize organ function is supported by ongoing study data, which allows for continuous monitoring of kidney metrics and protein expression. Within the biotechnology sector, such specialized clinical endpoints are becoming increasingly important for efficiently navigating regulatory requirements for treatments targeting rare genetic disorders.
By starting the rolling BLA process, Sangamo is advancing toward the completion of a full application. Following the final submission of all required modules, the FDA will establish an official review timeline and set a date for a final decision on marketing authorization.
Ad
Sangamo Therapeutics Stock: Buy or Sell?! New Sangamo Therapeutics Analysis from March 10 delivers the answer:
The latest Sangamo Therapeutics figures speak for themselves: Urgent action needed for Sangamo Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.
Sangamo Therapeutics: Buy or sell? Read more here...
